ライフサイエンスコーパス: multiple drug

1 complications arising from administration of multiple drugs.

2 particular drug and shared in resistance to multiple drugs.

3 election of pathogenic bacteria resistant to multiple drugs.

4 to substantial changes in susceptibility to multiple drugs.

5 al target for increasing chemosensitivity to multiple drugs.

6 ence to a minimum of 6 months treatment with multiple drugs.

7 d the first view of any MDR protein bound to multiple drugs.

8 toms was strongly associated with the use of multiple drugs.

9 selected the largest studies that evaluated multiple drugs.

10 o be allosterically modulated in presence of multiple drugs.

11 action (DDIs) occurs when a patient consumes multiple drugs.

12 ions used to map prevalence of resistance to multiple drugs.

13 olony variants (SCVs) which are resistant to multiple drugs.

14 safety of patients undergoing treatment with multiple drugs.

15 NTCP is also a target of multiple drugs.

16 urs within a year and exhibits resistance to multiple drugs.

17 the pervasiveness of cross-resistance across multiple drugs.

18 ffects than coadministration of a mixture of multiple drugs.

19 origin or the cancer subtypes for single or multiple drugs.

20 of a single-target drug or a combination of multiple drugs.

21 x system like DrrAB contains specificity for multiple drugs.

22 Ferumoxytol) can be utilized to carry one or multiple drugs.

23 preferentially associated with resistance to multiple drugs.

24 hs, especially when the child was exposed to multiple drugs.

25 eported to be associated with alcoholism and multiple drug abuse and dependence.

26 The pseudopersistence and likely presence of multiple drugs acting via the same mechanism of action,

27 siological response, and reduced reliance on multiple drug administration regimens.

28 in clinical practice to treat patients with multiple drugs, adverse events (AEs) are becoming a majo

29 with single drug allergy labels and 50 with multiple drug allergy labels.

30 ants lacking Pmr1 show growth sensitivity to multiple drugs (amiodarone, wortmannin, sulfometuron met

31 eed for lifelong coagulation monitoring, and multiple drug and diet interactions.

32 rent treatments involve the prolonged use of multiple drugs and are often ineffective.

33 it a powerful tool to evaluate the effect of multiple drugs and determine the most effective and pers

34 The ability to evaluate and cross-compare multiple drugs and drug combinations simultaneously in l

35 tability and allowed data to be obtained for multiple drugs and experimental conditions over hundreds

36 Multiple drugs and infectious agents can trigger the dis

37 ay demonstrated a high level of accuracy for multiple drugs and met the WHO's minimum target product

38 versatility of this formulation to integrate multiple drugs and provide sustained plasma concentratio

39 ecent identification of strains resistant to multiple drugs and the potential use of Y. pestis as an

40 sociates with risk of liver injury caused by multiple drugs and validated our finding in a separate c

41 ial for engaging and initiating transport of multiple drugs and xenobiotics.

42 tuberculosis (RR/MDR-TB) treatment requires multiple drugs, and outcomes remain suboptimal.

43 Multiple drug (antibiotic) resistance (MDR) has become a

44 Multiple drugs are available for this purpose.

45 However, multiple drugs are currently in development that could t

46 ical trials that meet today's standards, and multiple drugs are sought to counter resistance or use i

47 ovide simultaneous and prolonged delivery of multiple drugs, are often bulky and lack multifunctional

48 phenotypes, named accelerated resistance to multiple drugs (ARMD), raise important questions about t

49 could prevent drug resistance by delivering multiple drugs at therapeutically relevant concentration

50 tly inferring unknown DDIs from a network of multiple drug-based similarities and known interactions.

51 e labeling data also suggest the presence of multiple drug binding sites in ABCG2.

52 essful drugs target large gene families with multiple drug binding sites.

53 Cancer chemotherapy combines multiple drugs, but predicting the effects of drug combi

54 For drug discovery methods where multiple drug candidates can simultaneously bind to the

55 After adjustment for multiple drug characteristics, the mean proportion of to

56 was a prospective trial of 41 patients with multiple drug class-resistant HIV who were randomized to

57 ty of immune-modulating exposures, including multiple drug classes and disease states.

58 sms promoting the emergence of resistance to multiple drug classes have not been described in this or

59 As multiple drug classes progress in development, combinati

60 Multiple drug classes that do not affect weight in human

61 Despite the availability of multiple drug classes that modulate glycemia effectively

62 oss-sectional study, drug utilization across multiple drug classes was higher and drug costs were sig

63 Genes associated with resistance to multiple drug classes were observed in both species and

64 reat since it readily acquires resistance to multiple drug classes, including triazoles and/or echino

65 he Enterobacteriaceae are often resistant to multiple drug classes, making therapy of urinary infecti

66 erance and ultrahigh binding affinity toward multiple drug classes.

67 th deep denoising auto-encoder (DeepAMR) for multiple drug classification and developed DeepAMR_clust

68 ctive single agents, doublets, triplets, and multiple drug combination chemotherapy.

69 Here, to reduce the adverse effects of multiple drug combinations and improve outcome, we propo

70 In males, multiple drug combinations restored APD at 90% repolariz

71 s general for a variety of amines, including multiple drug compounds, and results in complete and sel

72 ins of the rat hippocampus were treated with multiple drug concentrations and temperatures.

73 tage clamp (VC) data from single iPSC-CMs at multiple drug concentrations.

74 out, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of m

75 ociated with major diseases and resistant to multiple drugs could be routinely delivered to individua

76 Testing the method on multiple drug datasets demonstrated an improved performa

77 ce its first report in 2014, CAGE has opened multiple drug delivery applications including transderma

78 ion has increased since the late 1990s, with multiple drugs developed that are shown to be effective

79 responsiveness to simultaneous microdoses of multiple drugs directly in a patient's tumor.

80 romoieties have been judiciously employed in multiple drug discovery campaigns, leading to three prod

81 manNet achieves state-of-the-art results for multiple drug discovery tasks, including molecular prope

82 other classes of cytotoxic drugs, we applied multiple drug effect/combination index (CI) isobologram

83 idrug resistance (MDR), which is mediated by multiple drug efflux ATP-binding cassette (ABC) transpor

84 ptional activators, activating expression of multiple drug exporters.

85 pproach demonstrated the capacity to recover multiple drug-exposed regions for in situ assessment of

86 ubation in an asthmatic adolescent receiving multiple drugs for anesthesia, in whom no sensitization

87 ases like HIV, pediatric patients are taking multiple drugs for effective treatments.

88 nstrument platforms, three laboratories, and multiple drug formulations following a comprehensive ana

89 in cystic fibrosis patients, can metabolize multiple drugs from different classes.

90 of different drugs, examples of delivery of multiple drugs from one MOF are rare, potentially hamper

91 indamycin, penicillin plus erythromycin, and multiple drugs (>/=3 antibiotics) was significantly lowe

92 methods, the ability of Sav1866 to transport multiple drugs has not been described.

93 between genetic mutations and resistance to multiple drugs have not been systematically evaluated.

94 us DTI network into a bipartite DTI network, multiple drug homogeneous networks and target homogeneou

95 itivity reactions have tendencies to develop multiple drug hypersensitivities (MDH).

96 Multiple drug hypersensitivity syndrome (MDH) is used to

97 Multiple drug hypersensitivity syndrome almost exclusive

98 clude viral reactivations, autoimmunity, and multiple drug hypersensitivity.

99 f the Theme II transplant models depended on multiple drug immunosuppression (Theme III, Immunology),

100 Current therapy rests on multiple-drug immunosuppression but its prognostic influ

101 on was added to the tacrolimus-steroid-based multiple drug immunosuppressions.

102 be necessary as part of a calcineurin-based multiple drug immunosuppressive regimen in low- to moder

103 formulation offers the ability to integrate multiple drugs in a single injection, which is particula

104 Moreover, genes identified by TG-LASSO for multiple drugs in a tissue were associated with patient

105 I-PISA performance on identifying targets of multiple drugs in cell lysate and scaling down the sampl

106 he speed for screening and identification of multiple drugs in equine plasma for doping control analy

107 course (6 to 9 mo) intermittent therapy with multiple drugs including isoniazid, ethambutol, pyrazina

108 sociated MRSA strains which are resistant to multiple drugs including vancomycin and daptomycin.

109 E strains and clinical isolates resistant to multiple drugs, including colistin.

110 Increasing resistance to multiple drugs, including quinolones, is associated with

111 taphylococcus aureus, protects the cell from multiple drugs, including quinolones.

112 fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed a

113 a single protein receiver that can integrate multiple drug inputs, including approved therapeutics.

114 In conclusion, we report that multiple drugs interact with OATP1B3-1B7; for ezetimibe,

115 K intake, common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynam

116 with cancer is often challenging because of multiple drug interactions, noncompliance, and intoleran

117 ues-an implantable microdevice to administer multiple drugs into different sites in tumors at nanodos

118 st becoming a big challenge as resistance to multiple drugs is rising rapidly.

119 ngular vaccine with the potential to display multiple drug-like antigens; thus two haptens were synth

120 al products and metabolites so as to improve multiple drug-like features of the parent molecule.

121 Moreover, NPs-mediated approaches facilitate multiple drug loading and targeted drug delivery, thereb

122 IM-MS evidenced ADC multiple drug loading, collisional cross sections measur

123 sporter is the efflux of spermidine, whereas multiple drugs may be recognized by Blt merely opportuni

124 tor (CAR; NR1I3) regulates the expression of multiple drug-metabolizing enzymes and transporters in l

125 stal engineering has also seen teams arrange multiple drug molecules within the same crystal, resulti

126 By use of data-dependent product ion scans, multiple drugs of abuse could be detected in a single dr

127 cocaine exposure, yet locomotor responses to multiple drugs of abuse were unaltered in the KO mice.

128 echanisms underlying behavioral responses to multiple drugs of abuse.

129 ity to interrupt the addictive properties of multiple drugs of abuse.

130 nd often severe side effects-especially when multiple drugs of the class are used simultaneously.

131 s advantages include simultaneous loading of multiple drugs, on-demand drug delivery controlled by ex

132 o nanocarriers and whether nanocarriers with multiple drugs outperform mixtures of single-drug nanoca

133 ore intensive continuation chemotherapy with multiple drug pairs administered in weekly rotation.

134 Multiple drug pairs identified in this study, including

135 Shorter multiple-drug preventive regimens have been proposed.

136 -tailored treatment versus clopidogrel under multiple drug pricing assumptions.

137 of an efflux pump that reduces the effect of multiple drugs provides an alternative pathway to sequen

138 titre broth micro-dilution assay (BMD) tests multiple drugs quantitatively.

139 y analyses examined the risk associated with multiple-drug regimens, including stimulants and antidep

140 tor and anti-interleukin-1], anti-CD-18, and multiple-drug regimes [combination of anti-tumor necrosi

141 h unexpected thrombocytopenia who are taking multiple drugs remains a difficult clinical problem.

142 The increase in bacterial resistance to multiple drugs represents a serious and growing health r

143 Multiple drug repurposing studies for COVID-19 are now u

144 irus-specific antiviral drugs has instigated multiple drug repurposing studies to redirect previously

145 centration was reversed by agents that block multiple drug resistance (MDR) and by the UIC2 anti-Pgp

146 Multiple drug resistance (MDR) as a result of overexpres

147 The murine multiple drug resistance (mdr) gene, mdr1a, encodes a 17

148 to enhance therapeutic efficacy by silencing multiple drug resistance (MDR) genes and resensitizing r

149 In a search for improved multiple drug resistance (MDR) modulators, we identified

150 sterone's ability to inhibit the activity of multiple drug resistance (MDR) P-glycoproteins.

151 pression of P-glycoprotein (P-gp) can confer multiple drug resistance (MDR) phenotype on cancer cells

152 therapeutic small interfering RNA (siRNA) to multiple drug resistance (MDR) tumors.

153 transplantation were related to CYP3AP1 and multiple drug resistance (MDR)-1 genotypes determined by

154 since colonizing strains frequently acquire multiple drug resistance (MDR).

155 and can acquire genetic material leading to multiple drug resistance (MDR).

156 safety and efficacy of transfer of the human multiple drug resistance (MDR1, MDR) gene into hematopoi

157 idermal growth factor receptor (EGFR), human multiple drug resistance 1 (MDR-1) and human proliferati

158 ase chain reaction (RT-PCR) amplification of multiple drug resistance 1 (MDR1) mRNA from high prolife

159 M1 is a substrate for P-glycoprotein and the multiple drug resistance 2 transporter.

160 Rapid development of multiple drug resistance against current therapies is a

161 e holoenzyme and activates genes involved in multiple drug resistance and redox homeostasis.

162 ew antimicrotubule compound that circumvents multiple drug resistance and so may be useful in the tre

163 as effective against P-glycoprotein-mediated multiple drug resistance and taxol resistance.

164 mosomal genes implicated in cell physiology, multiple drug resistance and virulence.

165 Multiple drug resistance due to P-glycoprotein (P-gp) ex

166 omology with components of fimbrial operons, multiple drug resistance efflux pumps and a haemolysin.

167 r drug accumulation, or amplification of the multiple drug resistance gene (MDR).

168 rmal growth factor receptor (EGFR) and human multiple drug resistance gene (MDR-1).

169 drugs used for selection in combination with multiple drug resistance gene 1 (MDR1) could have an enh

170 ith an amphotropic retrovirus containing the multiple drug resistance gene leads to gene transfer not

171 wo plasmids, R1 and RP4, both of which carry multiple drug resistance genes and were shown to impose

172 sive Campylobacter species clusters carrying multiple drug resistance genes that segregated with thes

173 tensive Campylobacter spp. clusters carrying multiple drug resistance genes that segregated with thes

174 n region V of CMV pol can, therefore, confer multiple drug resistance in a clinical isolate.

175 B operon is a regulatory locus that controls multiple drug resistance in Escherichia coli.

176 Prospective analysis of the role of multiple drug resistance in localized osteosarcoma did n

177 lle called vault, and has been implicated in multiple drug resistance in many cancer cell lines and p

178 nal infections may play an important role in multiple drug resistance in Mycobacterium avium infectio

179 lyzed prospectively to determine the role of multiple drug resistance in osteosarcoma.

180 many standard cytotoxic agents by means of a multiple drug resistance mechanism, remained quite susce

181 However, multiple drug resistance mechanisms can still emerge.

182 explore the hypothesis that the existence of multiple drug resistance mechanisms in different patient

183 r the taxanes in their ability to circumvent multiple drug resistance mechanisms.

184 All patients failing therapy showed multiple drug resistance mutations in different compartm

185 d reverse transcriptase sequences containing multiple drug resistance mutations, amplified from patie

186 nd that activates the ATPase activity of the multiple drug resistance P-glycoprotein, activated the m

187 of the MDR1 gene has been implicated in the multiple drug resistance phenotype expressed by many can

188 extrusion mechanisms including expression of multiple drug resistance proteins.

189 any neurological diseases, and the resulting multiple drug resistance represents a major clinical cha

190 her, our results support the hypothesis that multiple drug resistance to AEDs involves cerebrovascula

191 PB) cells, genetically marked with the human multiple drug resistance transgene (MDR1) were used for

192 The ATPase activity of the multiple drug resistance transporter Mdr1 (P-glycoprotei

193 n of the gene ABCB1 (also known as MDR1, for multiple drug resistance) in HeLa cells.

194 le CT18 carries two plasmids, one conferring multiple drug resistance, Ty2 has no plasmids and is sen

195 quisition of mutations in the development of multiple drug resistance.

196 sing candidate for treatment of cancers with multiple drug resistance.

197 nt transformation and conferring tumors with multiple drug resistance.

198 is, angiogenesis, response to infection, and multiple drug resistance.

199 and paclitaxel in the context of tumors with multiple drug resistance.

200 in the PDR1-101 transcription factor confers multiple drug resistance.

201 of cancer stem-like cells (CSC) that exhibit multiple drug resistance.

202 n, which codes for the Vibrio cholerae VceAB multiple-drug resistance (MDR) efflux pump, and vceR, wh

203 MATE transporters also mediate multiple-drug resistance (MDR) in bacteria and mammals,

204 Although poorly understood, in common with multiple-drug resistance (MDR) in tumors, MHR is associa

205 The multiple-drug resistance (MDR) transporter P-glycoprotei

206 Multiple-drug resistance and emerging fluoroquinolone re

207 recombination could contribute to high-level multiple-drug resistance and that this process must be c

208 ments often involve sequential selection for multiple-drug resistance in single ES cell lines, we hav

209 nt viruses and performed linkage analysis of multiple-drug resistance mutations.

210 in the proportion of T cells expressing the multiple-drug resistance pump P-glycoprotein.

211 Multiple drug-resistance bacteria (MDRB) infection is on

212 It harbors multiple drug-resistance elements including a truncated

213 The detection of multiple drug-resistance in Enterococcus including E. fa

214 Multiple drug-resistance interpretation algorithms have

215 lop resistance through stepwise selection of multiple drug-resistance mechanisms.

216 CT18 harbours a 218,150-bp multiple-drug-resistance incH1 plasmid (pHCM1), and a 10

217 Whole-genome sequencing of a multiple drug resistant (MDR) ST313 NTS isolate, D23580,

218 le outcome in TB and to mitigate the risk of multiple drug resistant (MDR)-TB, which is challenging t

219 l resistance to antibiotics, particularly to multiple drug resistant antibiotics, is becoming cause f

220 170-glycoprotein efflux pump associated with multiple drug resistant cancer cells.

221 has inhibitory activity against P-gp 170, a multiple drug resistant gene product.

222 Since the 1990s the rising incidence of multiple drug resistant TB, particularly in the context

223 ts an economical donor for the production of multiple-drug resistant MEFs.

224 xadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection

225 otypic screening of the mini library against multiple drug-resistant bacteria and a panel of cancer c

226 oduct sansalvamide A that are potent against multiple drug-resistant colon cancer cell lines.

227 alvamide A as an excellent lead for treating multiple drug-resistant colon cancers.

228 ide A as a privileged structure for treating multiple drug-resistant colon cancers.

229 InCs restore carbapenem activity against multiple drug-resistant Gram-negative bacteria and have

230 amine the efficacy of protegrin-1 in killing multiple drug-resistant microbes isolated from human bur

231 significantly associated with development of multiple drug-resistant organisms in IAI (P=0.032).

232 otics within 2 weeks before transplantation, multiple drug-resistant organisms often caused IAI.

233 such as increased levels of glutathione and multiple drug-resistant protein 4, these effects are unl

234 Against KB/7d cells (a pleiotrophic multiple drug-resistant subclone selected with etoposide

235 esent day thrust for new drugs to counteract multiple drug-resistant tuberculosis.

236 cent detection and recognition of widespread multiple-drug-resistant (MDR) and extensively drug-resis

237 ent of the major facilitator (MF) VceAB-VceC multiple-drug-resistant (MDR) efflux pump of Vibrio chol

238 se, viruses carrying various combinations of multiple-drug-resistant (MDR) mutations predominated wit

239 When concentrations of CBZ found in multiple-drug-resistant brain were directly applied to h

240 Of note is the response of slices from human multiple-drug-resistant brain, which was greater than in

241 ent in vitro and mouse-model efficacy toward multiple-drug-resistant fungal pathogens, exhibits a wid

242 f HIV infection, particularly infection with multiple-drug-resistant isolates.

243 ing standard antibiotics with protegrin-1 on multiple-drug-resistant microbial organisms isolated fro

244 ce of anaerobic bacteremia and prevalence of multiple-drug-resistant microorganisms.

245 In this paper, we have characterized a multiple-drug-resistant mutant of the HIV-1 protease tha

246 wder phage formulations for the treatment of multiple-drug-resistant pulmonary infections is gaining

247 osocomial pathogen with a high prevalence of multiple-drug-resistant strains, causing pneumonia and s

248 affect spheroid morphology, suggesting that multiple drug responses of VSMC spheroid formation exist

249 me of a S. typhi (CT18) that is resistant to multiple drugs, revealing the presence of hundreds of in

250 Furthermore, there are multiple drug reviews and prevalence studies.

251 uick (170-260 min) semiautomated analysis of multiple drug samples against the World Health Organizat

252 Multiple drug scaffolds were simultaneously docked into

253 to leverage multi-omics analysis to utilize multiple drug sensitivity induced by autophagy.

254 As a result, multiple drugs should be used.

255 The use of multiple drugs simultaneously targeting DNA is a promisi

256 g the properties of encapsulated drugs (even multiple drugs, simultaneously).

257 howed significant negative correlations with multiple drugs, suggesting a mechanism of drug resistanc

258 Multiple drug target analysis (MDTA) used in doping cont

259 Based on the prediction of multiple drug target pathway activation, we derive a com

260 using compounds and sequences as keys across multiple drug-target and enzymatic datasets, and gains r

261 he BET inhibitor JQ1 combined favorably with multiple drugs targeting B-cell receptor signaling, one

262 Therapies that combine multiple drugs targeting the same cellular pathway have

263 MS quantification of multiple drug targets and tissue proteotypes can improve

264 Single agents against multiple drug targets are of increasing interest.

265 At cytotoxic concentrations, amiloride has multiple drug targets including inhibition of NHE1 and s

266 The efficacy of engaging multiple drug targets using bispecific antibodies (BsAbs

267 22-associated diseases, with upregulation of multiple drug targets, including TNF and IL-23.

268 omated design of ligands against profiles of multiple drug targets.

269 It is essential for the virus and has multiple drug targets.

270 is essential for studying the virus and has multiple drug targets.

271 cting single chemical structures that target multiple drug targets.

272 Although there have been multiple drugs tested in gastroparesis, their relative e

273 anocarriers which simultaneously incorporate multiple drugs that affect different pathways and act th

274 his method was demonstrated by nomination of multiple drugs that are currently undergoing clinical tr

275 Multiple drugs that inhibit S1PR1 function are in use cl

276 Among multiple drugs that significantly increased the LMIs, we

277 In light of increased co-prescription of multiple drugs, the ability to discern and predict drug-

278 compliance with life-style modifications and multiple drug therapies should be explored.

279 EM is a complication of multiple drug therapy in patients awaiting heart transpl

280 ent of a long-acting technology that enables multiple drugs to be incorporated within one injectable

281 obilized, tethered to devices, and receiving multiple drugs to facilitate the entire process.

282 rption in the kidney(4), and are targeted by multiple drugs to treat diabetes(5).

283 Since use of multiple drugs to treat psychiatric patients is increasi

284 codes the primary transcription activator of multiple drug transporter genes in S. cerevisiae, includ

285 ngle cell phosphoquantitation in response to multiple drug treatment conditions and using limited pri

286 However, for long-term multiple-drug treatments, complications can arise from s

287 ected locally, through subsequent failure of multiple drugs until introduction of artemisinin combina

288 Substance misuse disorders, particularly multiple drug use, was more prevalent among individuals

289 sed in cell lines selected for resistance to multiple drugs used to treat acute leukemia.

290 naptic 5-HT inactivation and the targets for multiple drugs used to treat psychiatric disorders.

291 ons (mostly malaria and typhoid), and giving multiple drugs was common.

292 on to the development of HIV-1 resistance to multiple drugs was investigated.

293 ts are often given continuous treatment with multiple drugs well into old age.

294 Multiple drugs were used in the first few months of the

295 rror (chloramphenicol), and 15 minor errors (multiple drugs) were observed.

296 reatment might require either utilization of multiple drugs which target the individual pathological

297 mall molecule technologies for codelivery of multiple drugs with disparate solubility properties.

298 Our results point to multiple drugs with therapeutic potentials, including me

299 red, conversion to another active form; (ii) multiple drugs within a treatment combination; (iii) dif

300 ns also facilitates opportunities to combine multiple drugs within one delivery platform, as well as